Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1991 Aug 1;174(2):479–488. doi: 10.1084/jem.174.2.479

Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases

PMCID: PMC2118902  PMID: 1856630

Abstract

While close contact between lymphokine-activated killer (LAK)/adherent, lymphokine-activated killer (A-LAK) cells and tumor cells is believed to be a prerequisite for initiating the events leading to tumor cell lysis, clear evidence for the ability of these effector cells to infiltrate tumors or tumor metastases in vivo still has to be obtained. In the present study, we report that a significant fraction of adoptively transferred A-LAK cells, labeled with fluorochromes for identification, accumulates in lung and liver metastases of the B16 melanoma, the MCA 102 sarcoma and the Lewis lung carcinoma lines. Thus, 5- to 10-fold higher numbers of A-LAK cells were found in the malignant lesions compared to the surrounding normal tissue. The infiltration seemed very heterogeneous after intravenous injection of moderate numbers of A-LAK cells (15 x 10(6)). However, after adoptive transfer of 45 million A-LAK cells, an A-LAK cell/tumor cell ratio higher than 1:1 in most metastases was observed. Surprisingly, approximately 5% of the lung metastases seemed totally resistant to infiltration even though neighboring metastases were highly infiltrated. While substantial infiltration of lung metastases was seen after i.v. injection, significant infiltration of liver metastases was seen only after intraportal injection of the A-LAK cells indicating impaired traffic of intravenous injected A-LAK cells through the lung capillaries. These results present direct evidence that A-LAK cells, upon a proper route of administration, have the potential to migrate to and heavily infiltrate metastases from murine tumors of different origin.

Full Text

The Full Text of this article is available as a PDF (4.2 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ames I. H., Gagne G. M., Garcia A. M., John P. A., Scatorchia G. M., Tomar R. H., McAfee J. G. Preferential homing of tumor-infiltrating lymphocytes in tumor-bearing mice. Cancer Immunol Immunother. 1989;29(2):93–100. doi: 10.1007/BF00199283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Basse P., Hokland P., Heron I., Hokland M. Fate of tumor cells injected into left ventricle of heart in BALB/c mice: role of natural killer cells. J Natl Cancer Inst. 1988 Jul 6;80(9):657–665. doi: 10.1093/jnci/80.9.657. [DOI] [PubMed] [Google Scholar]
  3. Basse P., Hokland P., Hokland M. Comparison between 125IUdR and 51Cr as cell labels in investigations of tumor cell migration. Int J Rad Appl Instrum B. 1990;17(8):781–791. doi: 10.1016/0883-2897(90)90026-w. [DOI] [PubMed] [Google Scholar]
  4. Butcher E. C., Scollay R. G., Weissman I. L. Direct fluorescent labeling of cells with fluorescein or rhodamine isothiocyanate. II. Potential application to studies of lymphocyte migration and maturation. J Immunol Methods. 1980;37(2):109–121. doi: 10.1016/0022-1759(80)90196-9. [DOI] [PubMed] [Google Scholar]
  5. Butcher E. C., Weissman I. L. Direct fluorescent labeling of cells with fluorescein or rhodamine isothiocyanate. I. Technical aspects. J Immunol Methods. 1980;37(2):97–108. doi: 10.1016/0022-1759(80)90195-7. [DOI] [PubMed] [Google Scholar]
  6. Felgar R. E., Hiserodt J. C. In vivo migration and tissue localization of highly purified lymphokine-activated killer cells (A-LAK cells) in tumor-bearing rats. Cell Immunol. 1990 Sep;129(2):288–298. doi: 10.1016/0008-8749(90)90205-6. [DOI] [PubMed] [Google Scholar]
  7. Goldfarb R. H. Cell-mediated cytotoxic reactions. Hum Pathol. 1986 Feb;17(2):138–145. doi: 10.1016/s0046-8177(86)80286-6. [DOI] [PubMed] [Google Scholar]
  8. Gunji Y., Vujanovic N. L., Hiserodt J. C., Herberman R. B., Gorelik E. Generation and characterization of purified adherent lymphokine-activated killer cells in mice. J Immunol. 1989 Mar 1;142(5):1748–1754. [PubMed] [Google Scholar]
  9. Horan P. K., Slezak S. E. Stable cell membrane labelling. Nature. 1989 Jul 13;340(6229):167–168. doi: 10.1038/340167a0. [DOI] [PubMed] [Google Scholar]
  10. Hosokawa M., Sawamura Y., Morikage T., Okada F., Xu Z. Y., Morikawa K., Itoh K., Kobayashi H. Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide. Cancer Immunol Immunother. 1988;26(3):250–256. doi: 10.1007/BF00199937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Jain R. K. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst. 1989 Apr 19;81(8):570–576. doi: 10.1093/jnci/81.8.570. [DOI] [PubMed] [Google Scholar]
  12. Jain R. K. Determinants of tumor blood flow: a review. Cancer Res. 1988 May 15;48(10):2641–2658. [PubMed] [Google Scholar]
  13. Kleinman H. K., Martin G. R., Fishman P. H. Ganglioside inhibition of fibronectin-mediated cell adhesion to collagen. Proc Natl Acad Sci U S A. 1979 Jul;76(7):3367–3371. doi: 10.1073/pnas.76.7.3367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Lafreniere R., Rosenberg S. A. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. J Immunol. 1985 Dec;135(6):4273–4280. [PubMed] [Google Scholar]
  15. Maghazachi A. A., Herberman R. B., Vujanovic N. L., Hiserodt J. C. In vivo distribution and tissue localization of highly purified rat lymphokine-activated killer (LAK) cells. Cell Immunol. 1988 Aug;115(1):179–194. doi: 10.1016/0008-8749(88)90172-4. [DOI] [PubMed] [Google Scholar]
  16. Perkins R. M., Kellie S., Patel B., Critchley D. R. Gangliosides as receptors for fibronectin? Comparison of cell spreading on a ganglioside-specific ligand with that on fibronectin. Exp Cell Res. 1982 Oct;141(2):231–243. doi: 10.1016/0014-4827(82)90211-7. [DOI] [PubMed] [Google Scholar]
  17. Ratner S., Heppner G. H. Mechanisms of lymphocyte traffic in neoplasia. Anticancer Res. 1986 May-Jun;6(3 Pt B):475–482. [PubMed] [Google Scholar]
  18. Ratner S., Heppner G. H. Mechanisms of lymphocyte traffic in neoplasia. Anticancer Res. 1986 May-Jun;6(3 Pt B):475–482. [PubMed] [Google Scholar]
  19. Ratner S. Lymphocytes stimulated with recombinant human interleukin-2: relationship between motility into protein matrix and in vivo localization in normal and neoplastic tissues of mice. J Natl Cancer Inst. 1990 Apr 4;82(7):612–616. doi: 10.1093/jnci/82.7.612. [DOI] [PubMed] [Google Scholar]
  20. Rosenberg S. A., Lotze M. T. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu Rev Immunol. 1986;4:681–709. doi: 10.1146/annurev.iy.04.040186.003341. [DOI] [PubMed] [Google Scholar]
  21. Rosenstein M., Yron I., Kaufmann Y., Rosenberg S. A. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. Cancer Res. 1984 May;44(5):1946–1953. [PubMed] [Google Scholar]
  22. Sasaki A., Jain R. K., Maghazachi A. A., Goldfarb R. H., Herberman R. B. Low deformability of lymphokine-activated killer cells as a possible determinant of in vivo distribution. Cancer Res. 1989 Jul 15;49(14):3742–3746. [PubMed] [Google Scholar]
  23. Schwarz R. E., Vujanovic N. L., Hiserodt J. C. Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic. Cancer Res. 1989 Mar 15;49(6):1441–1446. [PubMed] [Google Scholar]
  24. Slezak S. E., Horan P. K. Fluorescent in vivo tracking of hematopoietic cells. Part I. Technical considerations. Blood. 1989 Nov 1;74(6):2172–2177. [PubMed] [Google Scholar]
  25. Wiltrout R. H., Gorelik E., Brunda M. J., Holden H. T., Herberman R. B. Assessment of in vivo natural antitumor resistance and lymphocyte. Migration in mice: comparison of 125I-iododeoxyuridine with 111indium-oxine and 51chromium as cell labels. Cancer Immunol Immunother. 1983;14(3):172–179. doi: 10.1007/BF00205356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Xiao J., Brahmi Z. Target cell-directed inactivation and IL-2-dependent reactivation of LAK cells. Cell Immunol. 1989 Sep;122(2):295–306. doi: 10.1016/0008-8749(89)90078-6. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES